1 Alpha synuclein aggresomes inhibit ciliogenesis and multiple functions of the centrosome

2

- 3 Anila Iqbal<sup>†</sup>, Marta Baldrighi<sup>†#</sup>, Jennifer N. Murdoch<sup>†</sup>, Angeleen Fleming<sup>‡</sup> and Christopher J.
- 4 Wilkinson<sup> $\dagger$ </sup>.
- 5
- 6 <sup>†</sup>Centre for Biomedical Sciences,
- 7 Department of Biological Sciences,
- 8 Royal Holloway University of London,
- 9 Egham,
- 10 Surrey,
- 11 TW20 0EX,
- 12 United Kingdom.
- 13
- <sup>14</sup> <sup>‡</sup>Department for Physiology, Development and Neuroscience,
- 15 University of Cambridge,
- 16 Cambridge,
- 17 CB2 3DY,
- 18 United Kingdom.
- 19 # Present address: Department of Medicine, University of Cambridge, Cambridge, UK.
- 20 Email: <u>christopher.wilkinson@rhul.ac.uk</u>
- 21
- 22 Running title: aggresomes and centrosomes/cilia
- 23
- 24 Keywords: Parkinson's disease, centrosome, aggresome, cilia, Lewy body, alpha-synuclein.

#### 26 Abstract

27 Protein aggregates are the pathogenic hallmarks of many different neurodegenerative 28 diseases and include the Lewy bodies found in Parkinson's disease. Aggresomes are closely-29 related cellular accumulations of misfolded proteins. They develop in a juxtanuclear position, 30 adjacent to the centrosome, the microtubule organizing centre of the cell, and share some 31 protein components. Despite the long-standing observation that aggresomes/Lewy bodies and 32 the centrosome sit side-by-side in the cell, no studies have been done to see whether these 33 protein accumulations impede the organelle function. We investigated whether the formation 34 of aggresomes affected key centrosome functions: its ability to organize the microtubule 35 network and to promote cilia formation. We find that when aggresomes are present, neuronal 36 cells are unable to organise their microtubule network. New microtubules are not nucleated 37 and extended, and the cells fail to respond to polarity cues. Since dopaminergic neurons are 38 polarised, ensuring correct localisation of organelles and the effective intracellular transport 39 of neurotransmitter vesicles, loss of centrosome activity could contribute to loss of 40 dopaminergic function and neuronal cell death in Parkinson's disease. In addition, we 41 provide evidence that many cell types, including dopaminergic neurons, cannot form cilia 42 when aggresomes are present, which would affect their ability to receive extracellular signals. 43 44 Introduction 45 46 Parkinson's disease is a progressive neurodegenerative condition that affects 1 in 500 47 of the population (Alves et al, 2008; Schrag et al, 2000; Van Den Eeden et al, 2003; von

48 Campenhausen et al, 2005). Dopaminergic neurons in the substantia nigra pars compacta are

49 first affected and the characteristic early symptom of Parkinson's disease is tremor (Alves et

al, 2008). As the disease progresses, other parts of the brain and nervous system are affected,

51 with dementia occurring in later stages. Within neurons of Parkinson's disease patients, large

52 alpha-synuclein -positive intracellular inclusions known as Lewy bodies are

53 observed (Wakabayashi et al, 2012). Increased  $\alpha$ -synuclein ( $\alpha$ -syn) levels, which occur in 54 rare cases with multiplication of the SNCA gene encoding it, are sufficient to cause 55 Parkinson's disease (Ibanez et al, 2004; Singleton et al, 2003) and mutations associated with 56 SNCA lead to an increase in aggregation propensity (Conway et al, 1998; Kruger et al, 1998; 57 Polymeropoulos et al, 1997). These mutations cause  $\alpha$ -syn to form oligomers and fibrils then 58 aggregates. Large aggregates of  $\alpha$ -syn constitute the Lewy bodies frequently found in the 59 neurons of Parkinson's disease patients (Baba et al, 1998; Spillantini et al, 1997). It is unclear 60 if these aggregates or Lewy bodies are a means to protect the cell from smaller unfolded units 61 of  $\alpha$ -syn or if these structures cause neuronal death by obstructing the normal function of the 62 cell. 63 Lewy bodies are observed in several diseases (Parkinson's disease, dementia with 64 Lewy bodies, incidental Lewy Body disease (Wakabayashi et al, 2012)) but are not found in 65 healthy cells and are related to the aggresome, a structure found in cells that are processing

66 large amounts of waste, unfolded polypeptide (Johnston et al, 1998). The aggresome is

67 juxtanuclear inclusion body containing heat-shock proteins and components of the ubiquitin-

68 proteasome system (Olzmann et al, 2008). These components are also found within Lewy

69 bodies and there are shared ultrastructural similarities. This has led to the proposal that Lewy

bodies are derived from aggresomes to specifically deal with misfolded α-syn (McNaught et
al, 2002; Olanow et al, 2004).

The juxtanuclear location of the aggresome is shared by the centrosome, the microtubule organising centre of the cell. Indeed, they sit side-by side and centrosomal markers such as gamma tubulin are often used to detect the aggresome, alongside the intermediate filaments such as vimentin that cage the structure (McNaught et al, 2002). While the position of the aggresome at the centre of the microtubule network has logic in terms of

77 transporting unfolded protein to a central location to be further processed (e.g. by 78 proteasomal degradation), it may affect the function of the centrosome, whose major role is 79 to organise this part of the cytoskeleton. Steric hindrance on a macromolecular scale may 80 perturb centrosome function. Furthermore, the centrosome is used to make the cilium. This 81 hair-like structure on the surface of cells has important roles both in motility, inter-cellular 82 communication and monitoring the external environment, with very specialised cilia housing 83 photopigments and olfactory receptors (Ibanez-Tallon et al, 2003; Nigg & Raff, 2009). To 84 make the cilium, the centrioles of the centrosome migrate to the cell surface, a process that 85 could be blocked by a large aggregate of protein smothering the centrosome or sticking it to 86 the nucleus. 87 The colocalization of the aggresome and centrosome and the sharing of protein 88 components has been known for nearly twenty years. However, it has not yet been tested if 89 this colocalization affects the function of the centrosome. This could have important 90 implications for the aetiology of Parkinson's disease and other neurodegenerative diseases in 91 which such aggregates are formed. In this study we sought to test whether multiple functions 92 of the centrosome were impeded by the presence of aggresomes in their close vicinity using 93 both *in vitro* and *in vivo* models. Our results suggest that inhibition of centrosome function 94 might contribute to loss of function in neurons where there is aggregation of alpha synuclein. 95 96 Results 97 98 Aggresomes localise in close proximity to the centrosome 99 We confirmed that we could induce the formation of aggresomes in a variety of cell types

100 using two previously published methods (Tanaka et al, 2004; Winslow et al, 2010). Cells

101 were either treated with MG-132, a proteasome inhibitor, or transfected with expression

102 constructs encoding GFP fusions of human  $\alpha$ -syn wildtype or mutant versions, A30P and 103 A53T, found in familial cases of Parkinson's disease (Kruger et al, 1998; Polymeropoulos et 104 al, 1997). The presence of aggresomes was then confirmed by staining with established 105 markers for aggresomes: anti-vimentin or anti-gamma tubulin antibodies (Johnston et al, 106 1998; Olanow et al, 2004; Wigley et al, 1999). We tested aggresome formation in SH-SY5Y 107 cells, a neuroblastoma line, either growing in continuous culture or after differentiation into 108 dopaminergic neurons if treated with retinoic acid, and in rat basal ganglion neurons. Using 109 both approaches, aggresome formation was observed, with vimentin caging the aggresomes 110 and gamma tubulin seen as a dense area of staining next to the nucleus instead of the usual 111 two punctae, representing the centrosome (Supplementary Fig. S1). Importantly, endogenous 112  $\alpha$  -syn was observed in aggresomes induced by MG-132, demonstrating that both methods 113 resulted in the accumulation of disease-associated, aggregate-prone proteins. These two 114 methods were used in parallel in the majority of studies, however, low transfection efficiency 115 prevented the use of the  $\alpha$ -syn overexpression constructs in differentiated SH-SY5Y cells or 116 rat basal ganglion neurons.

117

#### 118 Aggresomes suppress microtubule nucleation

119 The major function of the centrosome in interphase cells is the nucleation and 120 organisation of the microtubule network (Bornens, 2002). The ability of the centrosome to 121 nucleate microtubules can be assayed by the microtubule regrowth assay, in which the 122 microtubules are first depolymerised by cold treatment for 30 min (Fig 1, 37°C, t-30 column 123 vs  $4^{\circ}$ C, t = 0 column) followed by warming of the cells so that the centrosome can nucleate a 124 new network (Fig 1, columns 37°C, t+0.5' to 37°C, t+10') (De Brabander et al, 1986; Fry et 125 al, 1998). In control, untreated SH-SY5Y cells, the microtubules were nucleated after 30 s of 126 warming following depolymerisation, with a clear aster of alpha tubulin staining and an

127	extensive network after 10 min, as visualised by alpha tubulin staining (Fig. 1A, top row). In
128	contrast, cells treated with $1\mu M$ MG-132 for 24 h prior to the assay did not nucleate any
129	microtubules after 10 min warming (Fig 1A, second row), with only $5.3 \pm 0.58\%$ of treated
130	cells starting nucleation but $84 \pm 5.0\%$ of untreated cells making an aster (Fig. 1B 100 cells,
131	triplicate experiment). For SH-SY5Y cells transfected with expression constructs for GFP-
132	tagged $\alpha$ -syn, only 23 ± 3.5% of the cells initiated microtubule nucleation by 10 min whereas
133	$72 \pm 3.8\%$ of cells transfected with a control GFP expression plasmid re-established their
134	network within the same time (Fig. 1A third row, transfected cells delineated with dashed
135	line, identified by GFP expression (not shown); (GFP-transfected, familial mutant GFP
136	fusions and same data with GFP signal from transfected cells all shown in Supplementary
137	Fig. S2; 100 cells, triplicate experiment).
138	Due to the morphology of the cell and the number of stabilized microtubules, the
139	network and reforming aster is more difficult to observe in differentiated SH-SY5Y cells than
140	in continuously growing cell lines. Nevertheless, whereas untreated cells were able to reform
141	their labile microtubule network, differentiated SH-SY5Y cells were not, when aggresome
142	formation was induced by MG-132 treatment (Fig. 1 bottom two rows). $21 \pm 6.7\%$ of treated
143	cells were able to make an aster whereas $78 \pm 4.2\%$ of untreated cells re-establish their labile
144	microtubule network. Quantification is show in Fig. 1B & C.
145	

#### 146 Aggresomes prevent cell migration

147 The microtubule network is remodeled in response to polarity cues. This is exemplified by

148 cell migration, during which the Golgi and centrosome are re-orientated to face the direction

149 of cell locomotion. This function of the centrosome can be tested by the wound assay

150 developed by Hall (Nobes & Hall, 1999). A strip of cells is removed from a confluent culture

151 of an amenable cell line and those at the border of this wound will migrate to close the gap.

152	We tested the ability of cells to migrate in the presence of aggresomes induced by MG-132.
153	RPE1-hTERT cells generate aggresomes in the presence of 1 $\mu$ M MG-132 as assayed by
154	changes in gamma tubulin staining, from two punctae to a large area of signal close to the
155	nucleus (Fig. 2: A, untreated; B, treated). RPE1-hTERT cells can migrate and close a
156	'wound' in 12 h (Fig. 2D-G). In the presence of aggresomes generated by MG-132 treatment,
157	migration was halted with no cell movement to close the gap (Fig. 2H-K). Time-lapse
158	observations of treated and untreated cells (Supplementary Videos 1 and 2) clearly
159	demonstrate this lack of migration, quantified in Fig. 2C. The Golgi also did not re-orientate
160	as in control cells, with control cells' Golgi moving to face the wound (Fig. 2L vs M)
161	whereas in treated cells the Golgi remained randomly orientated (Fig. 2N vs O). 25% of the
162	wound was closed in treated cells versus near-complete wound closure for untreated cells. If
163	we measure the angle of the Golgi relative to a line perpendicular the wound, then treated
164	cells have a random orientation of the Golgi (average of 66.7° displacement from
165	perpendicular) whereas control cells are facing the wound (average of 44.2° displacement
166	from perpendicular) (Fig. 2P,Q).
167	

168 Aggresome formation inhibits ciliogenesis

169 We next tested if the presence of aggresomes prevents cells from making cilia as 170 ciliogenesis requires the centrioles of the centrosome to move to the cell surface where one 171 centriole templates the axoneme that forms the internal structure of the cilium. Many cell 172 types ciliate, but not all. To test whether aggresome inhibition of ciliogenesis might be 173 relevant to the dopaminergic neurons affected early in Parkinson's disease, we tested several 174 cell types for the presence of cilia by staining for acetylated tubulin together with gamma 175 tubulin to mark the basal bodies. Undifferentiated SH-SY5Y cells generated cilia when serum 176 starved and GFP expression did not affect ciliogenesis (Fig. 3A,B). Undifferentiated SH-

177 SY5Y cells failed to ciliate when treated with MG-132 (Fig. 3C) or when GFP- $\alpha$ -syn (any 178 variant, only wild-type  $\alpha$ -syn shown) was overexpressed (Fig. 3D). Quantification is shown 179 in Fig 3I.

180	Differentiated SH-SY5Y cells formed cilia as part of their differentiation programme
181	(Fig. 3E) but did not do so when treated with MG-132 (Fig. 3F). Rat basal ganglion cells are
182	ciliated under their normal culture conditions (Fig. 3G) but their ciliogenesis was much
183	reduced when treated with MG-132 (Fig. 3H). Quantification is shown in Fig. 3J,K.
184	To test whether aggresome formation affected ciliogenesis in an <i>in vivo</i> system, we
185	performed $\alpha$ -syn over-expression experiments in zebrafish embryos. Cilia are abundant in
186	zebrafish embryos and larvae and the olfactory pit in embryonic / larval zebrafish is highly
187	ciliated and accessible to observation. The ciliated cells of the olfactory pit are dopaminergic
188	neurons, as indicated by tyrosine hydroxylase (TH)-positive staining (Fig. 4 A). Treatment of
189	embryos with MG-132 caused loss of cilia at 3 dpf (Fig. 4: B, untreated; C, treated) with cilia
190	number being reduced from $65 \pm 11$ per pit to $15 \pm 6$ (Fig. 4I). We injected 1-cell embryos
191	with <i>in vitro</i> transcribed mRNA encoding human $\alpha$ -syn, (WT and familial mutants) and GFP
192	as a control (Fig. 4 D, E). Larvae were fixed at 2 dpf and assayed for olfactory cilia by
193	wholemount acetylated tubulin staining (Fig. 4 F, G; again familial mutants show same result
194	as WT $\alpha$ -syn). Cilia numbers were much reduced (11 ± 3.6 vs 41 ± 5.3 per pit) in the
195	olfactory zone when the embryos over expressed $\alpha$ -syn, any variant (Fig. 4H). The remaining
196	cilia were reduced in length, by approximately 50% from 8.4 $\pm$ 0.49 $\mu m$ to 4.7 $\pm$ 0.71 $\mu m$
197	(Fig. 4J). The gross anatomy of these embryos was otherwise normal (Fig 4D, E; data not
198	shown). Absence of cilia may be expected to cause other defects during embryogenesis, for
199	example hydrocephaly, left-right asymmetry defects and pronephric cysts. We did not
200	observe these defects. However, the effect on ciliogenesis at the olfactory pits was mild at 24

201 hpf. We therefore suspect that accumulation of  $\alpha$ -syn is required over several days to inhibit 202 ciliogenesis and so earlier stages escape the effects of aggresome-induced cilium loss.

203

#### 204 **Discussion**

205 Aggresomes occupy a central position in the cell, at the hub of the microtubule 206 network and that places them in the vicinity of the centrosome, the major microtubule 207 organising centre of the cell. Furthermore, the aggresome acquires an important centrosomal 208 component, gamma tubulin. We show here that aggresomes severely compromise centrosome 209 function. Microtubule nucleation is severely reduced and the centrosome is unable to be 210 repositioned during cell migration. These affects are observed whether the aggresomes are 211 generated by proteasome inhibition or alpha synuclein overexpression. Indeed MG-132 212 treatment generates aggresomes in which endogenous alpha synuclein accumulates. These 213 results and are consistent with and extend previous observations of the effect of MG-132 on 214 microtubule nucleation (Didier et al, 2008). A simple, steric hindrance of the centrosome is 215 the simplest and most likely explanation for this effect. 216 The centrosome is the main microtubule organising centre in the cell, nucleating 217 microtubules and anchoring a portion near to the nucleus. Its role as a major component of 218 the spindle poles is not important in mature neurons which do not divide. However, a 219 functioning, polarised microtubule network is still required for intracellular trafficking in a 220 terminally differentiated cell such as neurons and the centrosome is essential for maintaining 221 this. Much research on Parkinson's disease currently focusses on the mitochondrion (Exner et 222 al, 2012). Without a functioning centrosome and therefore a properly organised microtubule 223 network, it is likely that the mitochondria will themselves not be trafficked correctly in the 224 cell, with a particular impact on cells with a high energy demand, like neurons.

225 Most neurons do not migrate so the effect of aggresomes on cell migration is probably 226 not relevant to the development of Parkinson's disease. However, the inability of cells to 227 migrate and the Golgi to re-orientate in this situation provides a useful surrogate read-out for 228 the inability to repolarise the microtubule network in a desired direction. In mature neurons, 229 compromised cell polarity could have severe long-term effects on neuronal function and 230 survival. A polarised microtubule network is essential for the rapid trafficking of organelles 231 and vesicles, especially those containing neurotransmitters that need to be transported to 232 synapses, and the recycling of materials involved in neurotransmission. 233 Nearly all cell types make a cilium but neurons are one group of cells that contain 234 both unciliated (and centrosome possessing) sub-types and ciliated (acentrosomal) subtypes. 235 Our results show that aggresomes can prevent a cell from turning its centrosome into a 236 cilium. In Parkinson's disease, this may be relevant to those cells that undergo ciliogenesis. 237 An early symptom of Parkinson's disease is loss of smell and anosmia may precede other 238 symptoms (Doty et al, 1988; Haehner et al, 2007). It is not clear what the cause of anosmia 239 is, the assumption being that loss or impairment of neurons processing olfactory information 240 is the cause. An alternative explanation is that the olfactory neurons themselves are affected 241 during Parkinson's disease progression. Olfactory neurons are part of the dopaminergic 242 system (Pignatelli & Belluzzi, 2017) and the olfactory receptors are housed in cilia on these 243 cells. If early in the development of Parkinson's disease the ability of olfactory neurons to 244 renew cilia was compromised then so would the sense of smell. It may be possible, then, that 245 this early symptom is a result of gradual loss of cilia from olfactory neurons. If this is the 246 case, then cilia density in the olfactory epithelium of Parkinson's patients should be reduced 247 in age-matched controls. This hypothesis certainly warrants further investigation as it may 248 reveal that the olfactory cells are the sentinels of the dopaminergic system and anosmia 249 represents a first indicator of dopaminergic cell dysfunction. Should olfactory cilia be

accessible to routine screening, their number may be an early diagnostic tool for Parkinson'sdisease.

252	While we have provided clear evidence that aggresome formation affects centrosome
253	function in cell and in vivo models, proving that Lewy bodies affect microtubule nucleation
254	and cellular polarity in neurons of Parkinson's patients is likely to prove difficult. However,
255	it may be feasible to assay some of these effects in patient fibroblasts, which are more readily
256	accessible. Furthermore, since microtubule regrowth is a biochemical phenomenon whose
257	components may be capable of withstanding freezing it may be technically possible to
258	observe this in clinical samples obtained from brain bank tissue.
259	
260	<b>Materials and Methods</b>
261	Cell Culture
262 263	Cell lines used include: HeLa, provided by Prof George Dickson at Royal Holloway;
264	neuroblastoma cell line SH-SY5Y, provided by Prof Robin William at Royal Holloway;
265	immortalised human retinal pigment epithelial cells (RPE1-hTERT), kindly provided by Prof.
266	Erich Nigg, Basel, Switzerland; mouse embryonic fibroblast cells (MEFs), provided by Dr
267	Jenny Murdoch at Royal Holloway. Primary rat basal ganglion neurons were prepared by Dr
268	Simona Ursu at Royal Holloway.
269	
270	HeLa and SH-SY5Y cells were maintained in Dulbecco's Modified Eagle's Medium
271	(DMEM) supplemented with 10% Foetal Bovine Serum (FBS), 1x Antibiotic-Antimycotic
272	mix (Gibco; 5000 units of penicillin, 5000 $\mu$ g streptomycin and 15 $\mu$ g Amphotericin B) and
273	2mM L-glutamine. RPE1-hTERT were grown in Dulbecco's Modified Eagle's Medium with
274	nutrient mixture F-12 Ham (DMEMF-12) supplemented with 10% FBS, 1x Antibiotic-
275	Antimycotic (5000 units of penicillin, 5000µg streptomycin and 15µg Gibco Amphotericin

276	B), 2mM L- glutamine and 0.38% Sodium bicarbonate. MEFs were grown in DMEM
277	supplemented with 10% FBS, 1x Antibiotic-antimycotic, 2mM L- glutamine and 1x non-
278	essential amino acids. All cell lines were cultured at 37°C in a humidified atmosphere with
279	5% CO <sub>2</sub> . The same media mix was used for future experimental assays unless otherwise
280	stated.
281	
282	Primary Basal Ganglion neurons
283	
284	Primary cultures of basal ganglion neurons were prepared from E18 Sprague Dawley rat
285	embryos as previously described (Marsh et al, 2017). Briefly, cells were plated at a density
286	of either 75,000 or 500,000 cells on poly-D-lysine-coated (Sigma, 0.1 mg/ml in borate buffer
287	pH 8.5) 22mm <sup>2</sup> glass cover slips. The plating medium was DMEM supplemented with 5%
288	FBS, penicillin/streptomycin and 0.5 mM L-glutamine (all from Invitrogen). On the next day
289	the medium was changed to full Neurobasal medium (Neurobasal medium supplemented
290	with B27, 0.5 mM L-glutamine, all from Invitrogen). Cultures were incubated at 37 °C and
291	5% CO <sub>2</sub> , and were used at 18 days <i>in vitro</i> .
292	
293	SH-SY5Y Differentiation
294	
295	Cells were plated on collagen-coated coverslips in 12-well plates. Optimised seeding density
296	was calculated to be 6 X $10^4$ cells in 12-well culture plates. Cells were seeded out in DMEM
297	serum supplemented media, The media was replaced the following day with DMEM-F12

- supplemented with 1% FBS, 2mM L-Glutamine, 1x Antibiotic- Antimitotic mix (5000 units
- of penicillin, 5000µg streptomycin and 15µg Gibco Amphotericin B), 1 X non–essential

- amino acids and 10 µM all trans-retinoic acid (RA). Every two days the media was
- 301 replenished and after 7 days differentiation was observed.
- 302

#### 303 Aggresome formation

- 304
- 305 Aggresomes were induced by either treating cells with the proteasome inhibitor MG-132
- 306 (Sigma Aldrich) or by overexpressing GFP-tagged human  $\alpha$ -syn. The optimal MG-132
- 307 concentration was determined for each cell line ranging from  $1\mu$ M to  $10\mu$ M (HeLa,  $10\mu$ M;
- 308 SH-SY5Y, 1 µM; differentiated SH-SY5Y, 1µM; MEFs, 5 µM and rat neurons, 3 µM). MG-
- 309 132 was added to media for 18 hours at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>.
- 310
- 311 Constructs including peGFP-C2, peGFP-aSYN, peGFP-aSYNA30P and peGFP-aSYNA53T
- 312 were transiently transfected into cells. Lipofectamine 2000 (ThermoFisher) was used as the
- 313 transfection reagent following manufacturer's instruction. In brief, cells were plated onto
- 314 glass coverslips in serum-supplemented media without antibiotic-antimycotic mix. At 70%
- 315 confluency cells were transfected with DNA-lipid complexes (2.5 µg of plasmid DNA was
- diluted in 250 µL Opti-MEM + 10 µL of Lipofectamine 2000 reagent in 240 µL of Opti-
- 317 MEM). Complexes were added to each well for 5 hours at 37°C after which the media was
- replaced by low serum-supplemented media (DMEM, 1 % FBS, 2mM L-glutamine and 1%
- antibiotic-antimitotic mix for HeLa and SH-SY5Y; DMEM-F12, 1 % FBS, 1% antibiotic-
- antimitotic mix for RPE1-hTERT). Overexpression was achieved at 72 hours from the time
- 321 of transfection.

322

323 Microtubule re-growth assay

325	Cells were plated onto ethanol-washed glass coverslips in serum-supplemented media. At
326	70% confluency the samples were processed for the respective condition (MG-132 treatment
327	or overexpression of $\alpha$ -syn). The plate was incubated on ice for 30 min then pre-warmed
328	media (37°C) was added. Samples were fixed at different time points ranging from 0.5
329	minutes to 25 minutes, depending on the cell line, including immediately after 30 min on ice.
330	Cells were fixed for 10 min with methanol (-20°C), washed with PBS and stored in PBS.
331	
332	Ciliogenesis assay
333	
334	Cells were plated on glass coverslips in 6- or 12-well culture plates in serum-supplemented
335	media. Cells were treated with MG-132 or transfected with $\alpha$ -syn overexpression constructs
336	to form aggresomes. The media was replaced the following day with serum free media;
337	samples were incubated for 24 hours to induce cilia formation. Cells were fixed using 4%
338	(v/v) formaldehyde (FA) for 10 min. FA was aspirated and cells were washed with PBS.
339	Samples were stored in 0.2 % Triton in PBS until they were processed for
340	immunocytochemistry.
341	
342	Cells migration assay (Scratch-Wound Assay)
343	
344	MEFs and RPE1-hTERT were used in the wound assay. MEFs were plated onto collagen-
345	coated 35mm plastic Petri dishes. At 100 % confluency (with or without aggresome
346	formation using MG-132) a P200 pipetman tip was used to make wound. The media was
347	aspirated and washed twice with 1x PBS to remove detached cells. CO2 independent media
348	supplemented with 10% FBS, 2mM L-glutamine, 1 x antibiotic-antimycotic mix was added
349	for time-lapse experiments. Images were taken using a Nikon TE300 microscope with a 37°C

- 350 chamber, over a 24 hour period with images taken every 2 min. Similarly RPE1-hTERT cells
- 351 were plated onto ethanol-washed glass coverslips and treated with MG-132. Cell migration
- 352 was assessed by fixing cells at set time points with ice-cold methanol.
- 353

### 354 Golgi orientation

- A Golgi positioned within  $-45^{\circ}$  and  $+45^{\circ}$  of the wound was considered to be orientated
- towards the wound. The average angle of orientation was calculated using the formula
- 357  $(\Sigma\sqrt{\alpha^2})/n$  where  $\alpha$  is the angle between the Golgi and a line perpendicular to the wound edge.
- 358

## 359 Immunocytochemistry:

360

361 Cells were fixed with either methanol  $(-20^{\circ}C)$  or 4% (v/v) FA for 10 min. The fixative was 362 removed and washed with PBS (3 x 5 min). Cells were blocked in 3% BSA for 30 min at 363 room temperature. Cells were incubated with primary antibody in 1% BSA, either for 3 hours 364 at room temperature on a shaking platform or overnight at 4°C on a shaking platform. After 365 primary antibody incubation the cells were washed with PBS (3 x 5 min) and incubated with 366 secondary antibody for 1 hour at room temperature on a shaking platform. Cells were washed 367 with PBS (3 x 5 min), and mounted using FluorSave (Calbiochem). Primary antibodies used 368 were: rabbit anti-Tyrosine Hydroxylase (Merck-Millipore), 0.1 µg/ml; mouse anti-vimentin 369 (Sigma),  $1\mu g/ml$ ; mouse anti-acetylated-tubulin (Invitrogen)  $1\mu g/ml$ ; mouse anti- $\gamma$ -tubulin 370 (Sigma),  $1\mu g/ml$ ; rabbit anti- $\gamma$ -tubulin (Sigma),  $1\mu g/m$ ; mouse anti- $\alpha$ -tubulin (Sigma), 371  $1\mu g/ml$ ; rabbit anti- $\alpha$ -synuclein (Cell Signalling),  $10\mu g/ml$ ; mouse anti-Golgin 97 372 (ThermoFisher), 1µg/ml. Secondary antibodies used were: goat anti-mouse IgG, Alexa Fluor 373 594-conjugated (Invitrogen) 1µg/ml; goat anti-mouse IgG, Alexa Fluor 488-conjugated 374 (Invitrogen) 1µg/ml; and goat anti-rabbit IgG Alexa Fluor 488-conjugated (Invitrogen)
375 1µg/ml. Images were taken using a Nikon Ni-E fluorescence microscope.

376

#### 377 Whole mount immunostaining

378

379 Embryos were fixed with Dent's fixative (80:20, Methanol: DMSO) or 4% (v/v) FA

380 overnight at 4 °C. Fixative was removed the following day; embryos fixed with Dent's

fixative were stored in methanol at -20°C; FA fixed embryos were stored in PBS +0.2%

382 Triton. Embryos fixed with Dent's fixative were permeabilised by incubation in 100%

methanol for 30 mins at -20°C. Embryos were rehydrated by washing in serial dilution of

methanol in PBS including: MeOH:PBS at 70:30, 50:50 and 30:70 and final wash with PBS.

385 FA fixed embryos were permeabilised by incubation in 0.25% trypsin-EDTA in PBS for 10

386 min on ice and then washed three times for 30 min in PBS +0.02% Triton. Embryos were

blocked for 4 h in 10 % heat-inactivated goat serum, 1% bovine serum albumin and 0.2%

388 Triton in PBS. Embryos were incubated with primary and secondary antibodies for 36 h in

389 blocking solution. Primary antibodies used: rabbit anti-Tyrosine Hydroxylase (MERK

390 Millipore), 0.1 µg/ml; and mouse anti-acetylated-tubulin (Invitrogen) 1µg/ml. Secondary

antibodies used were goat anti-mouse IgG, Alexa Fluor 594-conjugated (Invitrogen) 1µg/ml;

and goat anti-rabbit IgG Alexa Fluor 488-conjugated (Invitrogen) 1µg/ml. Confocal stacks

393 were imaged with an Olympus FX81/FV1000 laser confocal system using Ar gas laser and

394 He-Ne diode laser. Stacks were taken in 1µm thickness and are represented as maximum-

intensity projections. Stacks were analysed using ImageJ.

396

397 mRNA synthesis

- 399 mRNAs were transcribed from the Sp6 promoter of the pCS2+-based plasmids encoding  $\alpha$ -
- 400 syn and mutant forms, using the mMessage mMachine in vitro transcription kit (Ambion,
- 401 TX, USA). RNA was purified using the Qiagen RNeasy kit (Qiagen).
- 402
- 403 Zebrafish
- 404
- 405 Zebrafish were maintained and bred at 26.5°C; embryos were raised at 28.5°C. Both AB and
- 406 TL wild-type strains were used for these studies. Embryos were processed by 3.d.p.f.. No
- 407 protected species, as defined by the Animals (Scientific Procedures) Act, 1986 were used for
- 408 experiments in this study. Embryos were injected into the yolk with mRNA using a
- 409 micromanipulator- mounted micropipette (Borosil  $1.0 \times 0.5$  mm, Frederick Haer & Co., Inc.,
- 410 USA) and a Picospritzer microinjector. Between 150-200pg of mRNA was injected into the
- 411 yolk of the embryos at 1-4 cell stage. For MG-132 treatment, embryos were treated with
- 412 50μM for 48 hours. Embryos processed for immunostaining were grown in 0.003%
- 413 phenylthiourea to inhibit melanin production. mRNA synthesis described below.
- 414

## 415 Statistics

- 416 Statistical tests used for each experiment are given in the figure legends. t-tests were used
- 417 when comparing two treatments and ANOVA for multiple treatments. n numbers represent
- the experimental unit, either number of embryos or separate cell culture experiments.

419

#### 420 Animal studies

- 421 No protected stages of zebrafish, as defined by the Animals (Scientific Procedures) Act,
- 422 1986, were used for experiments in this study, only fry less than 5 d.p.f.. Rats were killed by

423	Schedule 1 methods, according to Home Office regulations, in compliance with the Animals
424	(Scientific Procedures) Act, 1986.
425	
426	
427	Author contributions
428	AI performed the experiments under the supervision of CJW and JNM. AI prepared the
429	figures and legends. CJW wrote the main text. AF helped with study design and manuscript
430	preparation.
431	
432	Acknowledgements
433	We thank Dr Simona Ursu for assistance with the primary neuronal cultures.
434	Funding
435	This work was supported by Parkinson's UK Innovation Award K12/11.
436	<b>Conflicts of interest</b>
437	We declare that we have no conflicts of interest.
438	
439	Figure Legends
440	

441 Figure 1. Microtubule nucleation is disrupted in the presence of aggresomes in 442 undifferentiated and differentiated SH-SY5Y cells. A, top row) SH-SY5Y cells have an 443 extensive microtubule network. Upon cold treatment microtubules depolymerise. Upon 444 warming, microtubules nucleate from the centrosome forming a characteristic aster, which 445 continues to grow until the network is re-established. In SH-SY5Y cells the aster is seen 446 within in 30 seconds and the microtubule network is re-established within 10 min. A, row 2) 447 In the presence of aggresomes (1µM MG-132 for 18 hours) the centrosome is unable to 448 nucleate microtubules to re-establish this network. A, third row) Aggresomes formed by the 449 overexpression of  $\alpha$ -syn (GFP-fusion) had a similar affect: the centrosome is unable to re-450 establish the network in 10 min. A, row 4 and 5) In differentiated SH-SY5Y (tyrosine 451 hydroxylase in green). microtubule nucleation is seen as asters form from the centrosome 452 (arrow heads and inset). In the presence of aggresomes (1 $\mu$ M MG-132 for 18 hours) the 453 density of the network is reduced and microtubule nucleation is severely compromised with 454 staining of microtubules seen only in the last time point with no sign of asters forming. B) 455 Quantification of microtubule regrowth in undifferentiated and differentiated SH-SY5Y when 456 treated with MG-132 (p=0.0001, by Student's t-test, 100 cells, n=3). C) Ouantification of 457 microtubule regrowth in SH-SY5Y when α-synuclein is over-expressed (p=0.0001, one way-458 ANOVA, 100 cells, n=3). Microtubule nucleation and re-establishment of this network was 459 quantified by scoring cells (yes or no) whether the network was re-established in 10 mins. 460

## 462 Figure 2. Aggresomes reduce rate of cell migration and inhibit polarity changes. A-B) In 463 untreated RPE1-hTERT cells, $\gamma$ -tubulin stains the centrosome. Upon MG-132 treatment 464 (1µM for 18 hours) it stains the aggresome. C) The presence of aggresomes reduces the rate 465 of cell migration in the scratch-wound assay. D-G) RPE1 cells are able to migrate when a 466 strip of cells is removed from a monolayer of confluent cells. Complete wound closure is 467 observed by 8 hours. H-K) In the presence of aggresomes, minimal cell migration is detected. 468 L, M) In control cells the Golgi orientates from a random direction to face the leading edge of 469 the wound (Golgin-97, red). N, O) In the presence of aggresomes, this change in orientation 470 was not seen. P, Q) Quantification of change in angle of orientation during cell migration 471 with a schematic diagram showing how the Golgi orientation was measured. (p=0.0011, by 472 Student's t-test, 100 cells, n=3). Scale bars 10µm. Nuclei stained with DAPI (blue).

473

475 Figure 3. Aggresomes inhibits ciliogenesis. A, B) Undifferentiated SH-SH5Y cells form 476 cilia in serum free conditions or when transfected with a control GFP only expression 477 plasmid. C, D) When treated with MG-132 (1 $\mu$ M for 18 hours) or transfected with a GFP- $\alpha$ -478 syn expression plasmid, cilia formation is inhibited. E) Differentiated SH-SY5Y cells form 479 cilia in serum free conditions. F) In the presence of aggresomes (MG-132 1µm for 18 hours) 480 cilia are unable to form.  $\gamma$ -tubulin stains the aggresomes. G) Cilia are also found in TH-481 positive basal ganglion neurons, acetylated tubulin in red, TH in green. H) When treated 482 with MG-132 (3µM for 18 hours) cilia are no longer visible. I) Quantification of ciliation in 483 undifferentiated SH-SY5Y cells under various treatments (untreated vs. MG-132, p=0.0001, 484 by Student's t-test, 100 cell, n=3; GFP expressing vs. α-syn expression, p=0.0003, by one-485 way ANOVA, 100 cells, n=3). J) Quantification of cilia in differentiated SH-SY5Y cells 486 when treated with MG-132 (p=0.0001 by Student's t-test, 100 cells counted, n=3. K) 487 Quantification of cilia for basal ganglion neurons when treated with MG-132 (p=0.0126 by 488 Student's t-test, 100 cells counted, n=3). Scale bars 10µm. DNA/nuclei stained with DAPI 489 (blue).

490

491

492 Figure 4. Olfactory cilia in zebrafish embryos are severely reduced in the presence of 493 aggresomes. A) The neuronal dopaminergic network in 3 d.p.f. zebrafish forebrain viewed 494 from the dorsal aspect, detected by TH- staining (green). TH staining is also seen around the 495 olfactory pit. Acetylated tubulin (red) stains axon tracts and cilia. B) By 3 d.p.f extensive 496 numbers of cilia are visible at the olfactory pit. C) Embryos treated with MG-132 (50µM for 497 48 hours), showed an extensive reduction in number of cilia. D, E) Overexpression of control 498 GFP or  $\alpha$ -synuclein does not cause any anatomical defects in zebrafish larvae. F) In control 499 GFP-injected embryos, cilia are seen in the olfactory pit in large numbers. G) Overexpression 500 of any of the three forms of  $\alpha$ -syn severely reduces numbers of cilia. Cilia length is also 501 reduced. H) Quantification of cilia numbers in zebrafish embryos when  $\alpha$ -syn is over 502 expressed (p=0.001, by one-way ANOVA, n=3,). I) Quantification of length of cilia when  $\alpha$ -503 syn is overexpressed in zebrafish embryos (p=0.0088, by one-way ANOVA, n=3). J) 504 Quantification of cilia numbers when embryos are treated with MG-132 (p=0.0024, by 505 Student's t-test, n=4. Scale bar 100µm.

506

507 Supplementary Figure S1. SH-SY5Y cells form aggresomes when treated with MG-132. 508 Vimentin (A-A') (red) in control HeLa cells forms a fibrous network, around the nuclei 509 (DAPI- blue). (B-B') When treated with 10µM MG-132 for 18 hours, vimentin positive 510 aggresomes appear in cells, juxtaposed to the nucleus. The vimentin stain changes from a 511 filamentous stain around the nuclei to caging the aggresome. Similarly,  $\gamma$ -tubulin (red) 512 staining in control cells (C-C') labels the centrosomes as two punctae. Following MG-132 513 treatment,  $\gamma$ -tubulin forms a condensed structure around the aggresome (D-D'). The 514 expression pattern of endogenous  $\alpha$ -syn was also investigated to determine whether this 515 protein co-localises within the aggresome. (E'-E'') In control cells,  $\alpha$ -syn (green) staining 516 was widespread and diffuse within the cytoplasm with vimentin (red) forming a filamentous 517 network. (F'-F'') Following MG-132 treatment,  $\alpha$ -syn aggregates were observed and co-518 localised with vimentin staining within the aggresomes. (G'-G'') In control cells,  $\gamma$ -tubulin 519 (red) was observed as two punctae with  $\alpha$ -syn diffuse within the cytoplasm. (H-H'')  $\gamma$ -tubulin 520 staining (red) also co-localises with endogenous  $\alpha$ -syn in the aggresome when treated with 521 MG-132. Differentiated SH-SY5Y cells were mock-treated (I-I'') and vimentin (red) staining 522 was observed surrounding the nuclei as well as along the axon. J-J") Cells treated with MG-523 132 (1µM for 18 hours) vimentin staining changed to a compact structure near the nuclei, 524 indicative of aggresomes. K-K") In mock-treated cells  $\gamma$ -tubulin formed two punctae next to 525 the nucleus. L-L") In treated cells, aggresomes were detected by  $\gamma$ -tubulin staining.

526 Differentiated SH-SY5Y cells are TH positive. M-M'') In rat basal ganglion neurons, 527 vimentin staining (red) is abundant around the nuclei and along the axon. N-N'') When 528 treated with MG-132, vimentin localises to the aggresome. (O-O'') In rat basal ganglion 529 neurons, the  $\gamma$ -tubulin is observed at two punctae close to the nucleus. P-P'') Upon MG-132 530 treatment, the  $\gamma$ -tubulin staining now forms a larger structure next to the nucleus.

531

532 Supplementary Figure S2. Microtubule nucleation is disrupted in the presence of 533 aggresomes in undifferentiated SH-SY5Y cells. A) Top row, SH-SY5Y cells have an 534 extensive microtubule network. Upon cold treatment microtubules depolymerise. Upon 535 warming microtubules nucleate from the centrosome forming a characteristic aster, which 536 continues to grow until the network is re-established. In SH-SY5Y cells transfected with 537 GFP, the aster is seen within 30 seconds and the microtubule network is re-established within 538 in 10. A) Second and third rows: aggresomes formed by the over expression of GFP- $\alpha$ -539 synuclein ( $\alpha$ -SYN WT or  $\alpha$ SYNA30P) inhibited microtubule nucleation: the centrosome is 540 unable to re-establish the network in 10 min. Nuclei stained with DAPI (blue). B) Panels for 541 first and third rows of A shown with alpha tubulin staining only. Scale bar 100µm.

542

## 543 Supplementary Movie S1. Time-lapse of RPE1-hTERT migrating to close the wound.

544 Bright field view showing RPE1-hTERT cells migrate to close the wound when a strip of 545 cells is removed from a monolayer of confluent cells within in 12 hours.

546 Supplementary Movie S2. Time-lapse of RPE1-hTERT showing cells fail to close the

547 wound in the presence of aggresomes. Bright field view of RPE1-hTERT cells failing to

548 migrate and close the wound in the presence of aggresomes induced by MG-132 exposure.

- 549
- 550 551

#### References

- Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP (2008) Epidemiology of
- 553 Parkinson's disease. J Neurol 255 Suppl 5: 18-32
- 554
- 555 Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T
- 556 (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and
- 557 dementia with Lewy bodies. Am J Pathol 152: 879-884
- 558
- 559 Bornens M (2002) Centrosome composition and microtubule anchoring mechanisms. Curr
- 560 *Opin Cell Biol* **14:** 25-34
- 561
- 562 Conway KA, Harper JD, Lansbury PT (1998) Accelerated in vitro fibril formation by a
- mutant alpha-synuclein linked to early-onset Parkinson disease. *Nat Med* **4:** 1318-1320
- 564
- 565 De Brabander M, Geuens G, Nuydens R, Willebrords R, Aerts F, De Mey J (1986)
- 566 Microtubule dynamics during the cell cycle: the effects of taxol and nocodazole on the
- 567 microtubule system of Pt K2 cells at different stages of the mitotic cycle. Int Rev Cytol 101:

568 215-274

569

- 570 Didier C, Merdes A, Gairin JE, Jabrane-Ferrat N (2008) Inhibition of proteasome activity
- 571 impairs centrosome-dependent microtubule nucleation and organization. *Mol Biol Cell* **19**:
- 572 1220-1229

- 574 Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in parkinsonism: a general
- 575 deficit unrelated to neurologic signs, disease stage, or disease duration. *Neurology* 38: 1237-
- 576 1244

5	7	7	
J	1	1	

578	Exner N, Lutz AK, Haass C, Winklhofer KF (2012) Mitochondrial dysfunction in Parkinson's
579	disease: molecular mechanisms and pathophysiological consequences. EMBO J 31: 3038-
580	3062
581	
582	Fry AM, Meraldi P, Nigg EA (1998) A centrosomal function for the human Nek2 protein
583	kinase, a member of the NIMA family of cell cycle regulators. EMBO J 17: 470-481
584	
585	Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory
586	loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 22: 839-842
587	
588	Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A
589	(2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's
590	disease. Lancet 364: 1169-1171
591	
592	Ibanez-Tallon I, Heintz N, Omran H (2003) To beat or not to beat: roles of cilia in
593	development and disease. Hum Mol Genet 12: R27-35
594	
595	Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded
596	proteins. J Cell Biol 143: 1883-1898
597	
598	Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT,
599	Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in
600	Parkinson's disease. Nat Genet 18: 106-108
601	

- 602 Marsh J, Bagol SH, Williams RSB, Dickson G, Alifragis P (2017) Synapsin I
- 603 phosphorylation is dysregulated by beta-amyloid oligomers and restored by valproic acid.
- 604 Neurobiol Dis 106: 63-75
- 605
- 606 McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW (2002) Aggresome-related
- 607 biogenesis of Lewy bodies. *Eur J Neurosci* 16: 2136-2148
- 608
- 609 Nigg EA, Raff JW (2009) Centrioles, centrosomes, and cilia in health and disease. *Cell* 139:
- 610 663-678
- 611
- 612 Nobes CD, Hall A (1999) Rho GTPases control polarity, protrusion, and adhesion during cell
- 613 movement. J Cell Biol 144: 1235-1244
- 614
- 615 Olanow CW, Perl DP, DeMartino GN, McNaught KS (2004) Lewy-body formation is an
- aggresome-related process: a hypothesis. Lancet Neurol 3: 496-503
- 617
- 618 Olzmann JA, Li L, Chin LS (2008) Aggresome formation and neurodegenerative diseases:
- 619 therapeutic implications. *Curr Med Chem* **15:** 47-60
- 620
- 621 Pignatelli A, Belluzzi O (2017) Dopaminergic Neurones in the Main Olfactory Bulb: An
- 622 Overview from an Electrophysiological Perspective. *Front Neuroanat* 11:7
- 623
- 624 Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H,
- 625 Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A,
- 626 Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI,

- 627 Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with
- 628 Parkinson's disease. Science 276: 2045-2047
- 629
- 630 Schrag A, Ben-Shlomo Y, Quinn NP (2000) Cross sectional prevalence survey of idiopathic
- 631 Parkinson's disease and Parkinsonism in London. BMJ 321: 21-22
- 632
- 633 Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M,
- 634 Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler
- 635 C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K
- 636 (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841
- 637
- 638 Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-
- 639 synuclein in Lewy bodies. *Nature* **388**: 839-840
- 640
- Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM (2004) Aggresomes
- 642 formed by alpha-synuclein and synphilin-1 are cytoprotective. *J Biol Chem* 279: 4625-4631
- 643
- Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson
- 645 LM (2003) Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am
- 646 *J Epidemiol* **157:** 1015-1022
- 647
- 648 von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W,
- 649 Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson's disease in
- 650 Europe. Eur Neuropsychopharmacol 15: 473-490
- 651

- 652 Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H (2012) The Lewy Body in
- 653 Parkinson's Disease and Related Neurodegenerative Disorders. *Mol Neurobiol*
- 654
- 655 Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA,
- Lichtenberg M, Menzies FM, Ravikumar B, Imarisio S, Brown S, O'Kane CJ, Rubinsztein
- 657 DC (2010) alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. J
- 658 Cell Biol 190: 1023-1037
- 659



December 20, 2019. The copyright holder for this preprint iv a license to display the preprint in perpetuity. It is made ational license.





SH-SY5Y SH-SY5Y C https://doi.out/ulin1 А MG-132 Control D В GFP α<mark>syn</mark> SH-SY5Y differentiated Basal ganglion neurons γ- tubulin G Ε Control Control F γ- tubulin Н ΤН MG-132 MG-132

Ac-tubulin DAPI for all panels



01/2019.12.20.884643; this version posted December 20, 2019. The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig 3



December 20, 2019. The copyright holder for this preprint iv a license to display the preprint in perpetuity. It is made mational license.

Fig 4

B       Vimentin       B'       Vimentin       F'       0.5 Minute of the period	Α		A'	Vimentin +DAPI	E	Vimentin	E' *	αSYN	E"Overlay plus	DAPI	
B       Vimentin       B'       Vimentin       +DAPI         1µM MG-132       1µM MG-132       1µM MG-132       1µM MG-132       1µM MG-132         C       7- tubulin       C'       7- tubulin+DAPI       G       7- tubulin       G'       GSYN       G'' Overlay plus DAPI         D       0       0       0       0       0       0       0       0       0       0         1µM MG-132       1µM MG-132       1µM MG-132       1µM MG-132       1µM MG-132       0 <td></td> <td>(which y</td> <td></td> <td>nttps://doi.org/10.1 ified by peer ( w)</td> <td>101/20</td> <td>authernfunder, wie able under aCC-</td> <td></td> <td>sion posten De ranted bioRxiv ND 4.0 Internatio</td> <td>icense to display t nal license.</td> <td>the preprint in perpetuity. It is made</td> <td></td>		(which y		nttps://doi.org/10.1 ified by peer ( w)	101/20	authernfunder, wie able under aCC-		sion posten De ranted bioRxiv ND 4.0 Internatio	icense to display t nal license.	the preprint in perpetuity. It is made	
1μM MG-132       1μM MG-132       1μM MG-132       1μM MG-132       1μM MG-132         C       y-tubulin       C'       y-tubulin + DAPI       G       G       G       G         D       jum MG-132       D'       jum MG-132       H       Y-tubulin       H'       G       G       G         Image: How	В	Vimentin	B'	Vimentin +DAPI	F	Vimentin	F'	αSYN	F" Overlay plus	DAPI	
C $\gamma$ - tubulin       C' $\gamma$ - tubulin+DAPI       G $\alpha$ SYN       G''Overlay plus DAPI         D $\gamma$ - tubulin       D' $\gamma$ - tubulin       H $\gamma$ - tubulin       H'' Overlay plus DAPI         Image: D $\gamma$ - tubulin       D' $\gamma$ - tubulin       H'' $\alpha$ SYN       H'' Overlay plus DAPI         Image: D $\gamma$ - tubulin       D' $\gamma$ - tubulin       H'' $\alpha$ SYN       H'' Overlay plus DAPI         Image: D $\gamma$ - tubulin $\gamma$ - tubulin       H'' $\alpha$ SYN       H''' Overlay plus DAPI         Image: D $\gamma$ - tubulin         Image: D $\gamma$ - tubulin	1µM I	WG-132	1µM	MG-132	1µM N	1G-132	1µM MC	G-132 <b></b>	1µM MG-132		
D v tubulin d v tubulin v tubulin d v tubu	C	γ- tubulin	C'	γ- tubulin+DAPI	G	γ- tubulin	G'	αSYN	G"Overlay plus	DAPI	
	<b>D</b> 1μΜ <u>M</u>	γ- tübulin MG-132	<b>D'</b> 1µ <u>M</u>	γ- tubulin DAPI MG-132 — _	H	γ- tubulin	<b>Η'</b>	αSYN	H" Overlay plus	DAPI	
					-		ontict	od			

SH-SY5Y	differentiated

Vimentin	' TH	" Overlay plus DAPI	K γ- tubulin	К' тн	K" Overlay plus DAPI
			19 11		
				ste.	- A 1
J Vimentin	J' TH	J" Overlay plus DAPI	γ- tubulin	Ľ	L" Overlay plus DAPI
and the second s					
1µM MG-132	1µM MG-132	1µM MG-132	1µM MG-132	1µM MG-132	1µM MG-132

# Basal ganglion neurons

MVimentin	М' тн	M"Overlay plus DAPI	O y- tubulin	O' TH	O"Overlay plus DAPI
N Vimentin	N' <sup>TH</sup>	N" Overlay plus DAPI	P γ- tubulin	Р' тн.	P" Overlay plus DAP
3µM MG-132	3µM MG-132	3µM MG-132	3µM MG-132	3µM MG-132 🛛 💛 🔜	3µM MG-132



В



# Fig S 2